Rifaximin, but not growth factor 1, reduces brain edema in cirrhotic rats

World Journal of Gastroenterology

Volumn 18, Issue 17, 2012, Pages 2084-2091

  Òdena, Gemma ^a,b   Miquel, Mireia ^b,c   Serafín, Anna ^d   Galan, Amparo ^e   Morillas, Rosa ^b,e   Planas, Ramon ^a,b,e   Bartolí, Ramon ^a,b  

^a FUNDACIÓ INSTITUT D INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Servicio de Cirugía General Y Aparato Digestivo   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Cirrhosis; Hepatic encephalopathy; Hyperammonemia; Insulin like growth factor 1; Low grade brain edema; Rifaximin

Indexed keywords

ALANINE AMINOTRANSFERASE; AMMONIA; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBON TETRACHLORIDE; ENDOTOXIN; GLUCOSE; GLUTAMINE; PLACEBO; RIFAXIMIN; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BODY WEIGHT; BRAIN EDEMA; BRAIN WATER; CONTROLLED STUDY; ENDOTOXEMIA; HISTOPATHOLOGY; HYPERAMMONEMIA; LIVER CIRRHOSIS; MALE; NONHUMAN; PLASMA; PORTAL VEIN OBSTRUCTION; RAT;

EID: 84860576212     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v18.i17.2084     Document Type: Article

References (35)

1. Butterworth RF. Pathogenesis of hepatic encephalopathy: new insights from neuroimaging and molecular studies. J Hepatol 2003; 39: 278-285
2. Córdoba J, Mínguez B. Hepatic encephalopathy. Semin Liver Dis 2008; 28: 70-80
3. O'Leary JG, Lepe R, Davis GL. Indications for liver transplantation. Gastroenterology 2008; 134: 1764-1776
4. Felipo V, Butterworth RF. Neurobiology of ammonia. Prog Neurobiol 2002; 67: 259-279
5. Olde Damink SW, Jalan R, Redhead DN, Hayes PC, Deutz NE, Soeters PB. Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology 2002; 36: 1163-1171
6. Butterworth RF, Giguère JF, Michaud J, Lavoie J, Layrargues GP. Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol 1987; 6: 1-12
7. Hoover WW, Gerlach EH, Hoban DJ, Eliopoulos GM, Pfaller MA, Jones RN. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis 1993; 16: 111-118
8. Bachmann C. Mechanisms of hyperammonemia. Clin Chem Lab Med 2002; 40: 653-662
9. Romero-Gómez M, Jover M, Galán JJ, Ruiz A. Gut ammonia production and its modulation. Metab Brain Dis 2009; 24: 147-157
10. Mas A, Rodés J, Sunyer L, Rodrigo L, Planas R, Vargas V, Castells L, Rodríguez-Martínez D, Fernández-Rodríguez C, Coll I, Pardo A. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003; 38: 51-58
11. Neff GW, Kemmer N, Zacharias VC, Kaiser T, Duncan C, McHenry R, Jonas M, Novick D, Williamson C, Hess K, Thomas M, Buell J. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc 2006; 38: 3552-3555
12. Williams R, James OF, Warnes TW, Morgan MY. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 2000; 12: 203-208
13. Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993; 13: 109-118
14. Alcorn J. Review: rifaximin is equally or more effective than other antibiotics and lactulose for hepatic encephalopathy. ACP J Club 2008; 149: 11
15. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 1071-1081
16. Venturini AP, Marchi E. In vitro and in vivo evaluation of L/105, a new topical intestinal rifamycin. Chemioterapia 1986; 5: 257-262
17. Descombe JJ, Dubourg D, Picard M, Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994; 14: 51-56
18. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3-34
19. Fernández-Rodriguez CM, Prada I, Andrade A, Moreiras M, Guitián R, Aller R, Lledó JL, Cacho G, Quiroga J, Prieto J. Disturbed synthesis of insulinlike growth factor I and its binding proteins may influence renal function changes in liver cirrhosis. Dig Dis Sci 2001; 46: 1313-1320
20. Castilla-Cortazar I, Garcia M, Muguerza B, Quiroga J, Perez R, Santidrian S, Prieto J. Hepatoprotective effects of insulinlike growth factor I in rats with carbon tetrachlorideinduced cirrhosis. Gastroenterology 1997; 113: 1682-1691
21. Muguerza B, Castilla-Cortázar I, García M, Quiroga J, Santidrián S, Prieto J. Antifibrogenic effect in vivo of low doses of insulin-like growth factor-I in cirrhotic rats. Biochim Biophys Acta 2001; 1536: 185-195
22. Castilla-Cortazar I, Prieto J, Urdaneta E, Pascual M, Nuñez M, Zudaire E, Garcia M, Quiroga J, Santidrian S. Impaired intestinal sugar transport in cirrhotic rats: correction by low doses of insulin-like growth factor I. Gastroenterology 1997; 113: 1180-1187
23. Lorenzo-Zúñiga V, Rodríguez-Ortigosa CM, Bartolí R, Martínez-Chantar ML, Martínez-Peralta L, Pardo A, Ojanguren I, Quiroga J, Planas R, Prieto J. Insulin-like growth factor I improves intestinal barrier function in cirrhotic rats. Gut 2006; 55: 1306-1312
24. Miquel M, Bartolí R, Odena G, Serafín A, Cabré E, Galan A, Barba I, Córdoba J, Planas R. Rat CCl(4)-induced cirrhosis plus total portal vein ligation: a new model for the study of hyperammonaemia and brain oedema. Liver Int 2010; 30: 979-987
25. Runyon BA, Sugano S, Kanel G, Mellencamp MA. A rodent model of cirrhosis, ascites, and bacterial peritonitis. Gastroenterology 1991; 100: 489-493
26. Lebrec D. Animal models of portal hypertension. In: Okuda K, Benhamou JP. Portal hypertension. Clinical and Physiological aspects. Tokyo: Springer-Verlag, 1991: 101-113
27. Guarner C, Runyon BA, Young S, Heck M, Sheikh MY. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol 1997; 26: 1372-1378
28. Vogels BA, van Steynen B, Maas MA, Jörning GG, Chamuleau RA. The effects of ammonia and portal-systemic shunting on brain metabolism, neurotransmission and intracranial hypertension in hyperammonaemia-induced encephalopathy. J Hepatol 1997; 26: 387-395
29. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-374
30. Jirillo E, Caccavo D, Magrone T, Piccigallo E, Amati L, Lembo A, Kalis C, Gumenscheimer M. The role of the liver in the response to LPS: experimental and clinical findings. J Endotoxin Res 2002; 8: 319-327
31. Paik YH, Lee KS, Lee HJ, Yang KM, Lee SJ, Lee DK, Han KH, Chon CY, Lee SI, Moon YM, Brenner DA. Hepatic stellate cells primed with cytokines upregulate inflammation in response to peptidoglycan or lipoteichoic acid. Lab Invest 2006; 86: 676-686
32. Zapater P, Caño R, Llanos L, Ruiz-Alcaraz AJ, Pascual S, Barquero C, Moreu R, Bellot P, Horga JF, Muñoz C, Pérez J, García-Peñarrubia P, Pérez-Mateo M, Such J, Francés R. Norfloxacin modulates the inflammatory response and directly affects neutrophils in patients with decompensated cirrhosis. Gastroenterology 2009; 137: 1669-1679. e1
33. Pardo A, Bartolí R, Lorenzo-Zúñiga V, Planas R, Viñado B, Riba J, Cabré E, Santos J, Luque T, Ausina V, Gassull MA. Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis. Hepatology 2000; 31: 858-863
34. Miglioli PA, Allerberger F, Calabrò GB, Gaion RM. Effects of daily oral administration of rifaximin and neomycin on faecal aerobic flora in rats. Pharmacol Res 2001; 44: 373-375
35. Yang J, Lee HR, Low K, Chatterjee S, Pimentel M. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci 2008; 53: 169-174